Emerging Roles of Using Small Extracellular Vesicles as an Anti-Cancer Drug

Int J Mol Sci. 2023 Sep 14;24(18):14063. doi: 10.3390/ijms241814063.

Abstract

Small extracellular vesicles (sEVs) are emerging as a novel therapeutic strategy for cancer therapy. Tumor-cell-derived sEVs contain biomolecules that can be utilized for cancer diagnosis. sEVs can directly exert tumor-killing effects or modulate the tumor microenvironment, leading to anti-cancer effects. In this review, the application of sEVs as a diagnostic tool, drug delivery system, and active pharmaceutical ingredient for cancer therapy will be highlighted. The therapeutic efficacies of sEVs will be compared to conventional immune checkpoint inhibitors. Additionally, this review will provide strategies for sEV engineering to enhance the therapeutic efficacies of sEVs. As a bench-to-bedside application, we will discuss approaches to encourage good-manufacturing-practice-compliant industrial-scale manufacturing and purification of sEVs.

Keywords: cancer biomarker; cancer therapy; drug delivery system; exosome; extracellular vesicle; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Commerce
  • Drug Delivery Systems
  • Extracellular Vesicles*
  • Immune Checkpoint Inhibitors

Substances

  • Antineoplastic Agents
  • Immune Checkpoint Inhibitors